PL3536776T3 - Nowe komórki kręgowców i sposoby ekspresji rekombinowanej polipeptydu będącego przedmiotem zainteresowania - Google Patents

Nowe komórki kręgowców i sposoby ekspresji rekombinowanej polipeptydu będącego przedmiotem zainteresowania

Info

Publication number
PL3536776T3
PL3536776T3 PL19161388.4T PL19161388T PL3536776T3 PL 3536776 T3 PL3536776 T3 PL 3536776T3 PL 19161388 T PL19161388 T PL 19161388T PL 3536776 T3 PL3536776 T3 PL 3536776T3
Authority
PL
Poland
Prior art keywords
polypeptide
interest
methods
vertebrate cells
recombinantly expressing
Prior art date
Application number
PL19161388.4T
Other languages
English (en)
Inventor
Holger Laux
Sandrine Romand
Ursula Bodendorf
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53682742&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3536776(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL3536776T3 publication Critical patent/PL3536776T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21109Matriptase (3.4.21.109)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10Investigating individual particles
    • G01N15/14Optical investigation techniques, e.g. flow cytometry
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • C12N2510/02Cells for production
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/01Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10Investigating individual particles
    • G01N2015/1006Investigating individual particles for cytology

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
PL19161388.4T 2014-04-29 2015-04-29 Nowe komórki kręgowców i sposoby ekspresji rekombinowanej polipeptydu będącego przedmiotem zainteresowania PL3536776T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461985589P 2014-04-29 2014-04-29
US201461994310P 2014-05-16 2014-05-16

Publications (1)

Publication Number Publication Date
PL3536776T3 true PL3536776T3 (pl) 2024-03-25

Family

ID=53682742

Family Applications (2)

Application Number Title Priority Date Filing Date
PL15739327T PL3137595T3 (pl) 2014-04-29 2015-04-29 Nowe komórki kręgowców i sposoby ekspresji rekombinowanej polipeptydu będącego przedmiotem zainteresowania
PL19161388.4T PL3536776T3 (pl) 2014-04-29 2015-04-29 Nowe komórki kręgowców i sposoby ekspresji rekombinowanej polipeptydu będącego przedmiotem zainteresowania

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL15739327T PL3137595T3 (pl) 2014-04-29 2015-04-29 Nowe komórki kręgowców i sposoby ekspresji rekombinowanej polipeptydu będącego przedmiotem zainteresowania

Country Status (17)

Country Link
US (2) US11512335B2 (pl)
EP (3) EP3137595B1 (pl)
JP (1) JP6636453B2 (pl)
KR (1) KR102307278B1 (pl)
CN (1) CN106255749A (pl)
AU (1) AU2015254913B2 (pl)
CA (1) CA2947198C (pl)
DK (2) DK3137595T3 (pl)
ES (2) ES2731246T3 (pl)
IL (1) IL248184B (pl)
LT (2) LT3536776T (pl)
MX (1) MX368664B (pl)
PL (2) PL3137595T3 (pl)
PT (2) PT3536776T (pl)
RU (1) RU2710726C2 (pl)
SG (1) SG11201608358VA (pl)
WO (1) WO2015166427A2 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3015475A1 (en) 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens
NZ760116A (en) 2017-06-22 2024-03-22 Vertex Pharma Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use
WO2019180607A1 (en) * 2018-03-19 2019-09-26 Centre For Cellular And Molecular Platforms A vector, a host cell and a method thereof
CR20220107A (es) 2019-09-18 2022-04-25 Novartis Ag Proteínas de fusión nkg2d y sus usos
US20210244821A1 (en) 2020-02-05 2021-08-12 Novartis Ag Cho cell expressed het il-15
JP2023527693A (ja) * 2020-05-11 2023-06-30 ジェネンテック, インコーポレイテッド 神経疾患を治療するための補体成分c1r阻害剤、並びに関連する組成物、システム、及びそれを使用する方法
WO2023223219A1 (en) * 2022-05-19 2023-11-23 Novartis Ag IMPROVED PROTEIN PRODUCTION USING miRNA TECHNOLOGY

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
CA2096222C (en) 1990-11-13 1998-12-29 Stephen D. Lupton Bifunctional selectable fusion genes
US5371198A (en) * 1991-12-16 1994-12-06 Novo Nordisk A/S Method for protection of proteolysis-susceptible protein during protein production in a fluid medium
EP0804590A1 (en) 1993-05-21 1997-11-05 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
AU2001278488A1 (en) 2000-07-25 2002-02-05 Bayer Aktiengesellschaft Regulation of human matriptase-like serine protease
CN100513414C (zh) 2001-08-27 2009-07-15 杰南技术公司 进行抗体表达和装配的***
WO2004031733A2 (en) * 2002-10-02 2004-04-15 Catalyst Biosciences Methods of generating and screenign for porteases with altered specificity
EP1601776B1 (en) 2003-03-11 2008-07-02 Laboratoires Serono SA Expression vectors comprising the mcmv ie2 promoter
ATE454474T1 (de) * 2004-08-10 2010-01-15 Cardiff Biolog Ltd Verfahren und kit zur prognose von brustkrebs
AU2005319404B2 (en) 2004-12-20 2011-10-20 Amgen Fremont Inc. Binding proteins specific for human Matriptase
US7632509B2 (en) * 2005-07-19 2009-12-15 Biosante Pharmaceuticals, Inc. Methods to express recombinant proteins from lentiviral vectors
WO2009021754A2 (en) 2007-08-15 2009-02-19 Bayer Schering Pharma Aktiengesellschaft Monospecific and multispecific antibodies and method of use
JP5660900B2 (ja) 2007-12-21 2015-01-28 ノバルティス アーゲー 有機化合物
EP2398494A4 (en) 2009-02-23 2015-10-28 Cytomx Therapeutics Inc Proproteins and their methods of use
RU2535986C2 (ru) 2009-02-27 2014-12-20 Новартис Аг Система векторов экспрессии, включающая два селективных маркера
US8722964B2 (en) * 2009-04-23 2014-05-13 Transposagen Biopharmaceuticals, Inc. Genetically engineered or transgenic rats exhibiting a cancer phenotype due to a disruption of germline tumor suppressor genes
WO2011134920A1 (en) 2010-04-26 2011-11-03 Novartis Ag Improved cell culture medium
ES2676412T3 (es) 2011-06-02 2018-07-19 Socpra Sciences Santé Et Humaines S.E.C. Inhibidores de matriptasa y usos de los mismos contra infecciones por ortomixovirus
PE20150605A1 (es) * 2012-04-27 2015-05-28 Cytomx Therapeutics Inc Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico
RU2015101803A (ru) * 2012-06-22 2016-08-20 Сайтомкс Терапьютикс, Инк. Перекрестно реактивные антитела к jagged 1/k jagged 2, активируемые антитела к jagged и способы их применения
EP3015475A1 (en) * 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens

Also Published As

Publication number Publication date
RU2710726C2 (ru) 2020-01-10
AU2015254913A1 (en) 2016-10-27
LT3137595T (lt) 2019-06-25
WO2015166427A2 (en) 2015-11-05
US11512335B2 (en) 2022-11-29
AU2015254913B2 (en) 2018-05-17
ES2968879T3 (es) 2024-05-14
CA2947198A1 (en) 2015-11-05
US20230323419A1 (en) 2023-10-12
EP3536776B1 (en) 2023-10-25
EP3137595A2 (en) 2017-03-08
IL248184B (en) 2021-03-25
ES2731246T3 (es) 2019-11-14
LT3536776T (lt) 2024-01-25
RU2016145928A (ru) 2018-05-29
SG11201608358VA (en) 2016-11-29
CN106255749A (zh) 2016-12-21
PT3137595T (pt) 2019-06-19
KR20160147919A (ko) 2016-12-23
RU2016145928A3 (pl) 2018-12-26
US20170044587A1 (en) 2017-02-16
MX368664B (es) 2019-10-10
MX2016014222A (es) 2017-05-04
BR112016024534A2 (pt) 2017-10-10
JP2017514484A (ja) 2017-06-08
EP3137595B1 (en) 2019-03-13
KR102307278B1 (ko) 2021-09-30
PT3536776T (pt) 2024-01-12
EP4332231A3 (en) 2024-05-29
WO2015166427A3 (en) 2016-01-14
EP4332231A2 (en) 2024-03-06
IL248184A0 (en) 2016-11-30
DK3536776T3 (da) 2024-01-15
DK3137595T3 (da) 2019-06-17
JP6636453B2 (ja) 2020-01-29
EP3536776A1 (en) 2019-09-11
CA2947198C (en) 2023-01-17
PL3137595T3 (pl) 2019-09-30

Similar Documents

Publication Publication Date Title
HK1232239A1 (zh) 細胞穿透肽及其製造和使用方法
EP3240799A4 (en) S-alkylated hepcidin peptides and methods of making and using thereof
IL248361A0 (en) Recombinant host cell for expression of desired proteins
IL248184B (en) Novel invertebrate cells and methods for recombinant expression of a desired polypeptide
IL245854A0 (en) New eukaryotic cells and methods for recombinant expression of the desired product
HK1244460A1 (zh) 絲氨酸融合多肽和其使用方法
IL245856B (en) New eukaryotic cells and methods for recombinant expression of the desired product
IL237993A0 (en) Incorporating pixels and operating methods
IL246642A0 (en) Materials and methods for quantifying pld-1 protein levels
EP3268477A4 (en) Structure based methods for modification of pip-72 polypeptides and pip-72 polypeptides derived therefrom
EP3092248A4 (en) Fusion polypeptides and methods of use
IL250178A0 (en) Methods and preparations for the expression of peptides in the cell
IL247448A0 (en) Peptides and methods of use
GB2527908B (en) Closure means and method of use thereof
PL2957516T3 (pl) Pojemnik i sposób jego produkcji